Chloroquine NEW
| Price | $42 | $145 |
| Package | 100mg | 500mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-17 |
Product Details
| Product Name: Chloroquine | CAS No.: 54-05-7 |
| Purity: 99.95% | Supply Ability: 10g |
| Release date: 2026/07/17 |
Product Introduction
Bioactivity
| Name | Chloroquine |
| Description | Chloroquine is a Toll-like receptor inhibitor that inhibits autophagy. Chloroquine has anti-malarial and anti-inflammatory activity and is widely used in the treatment of malaria and rheumatoid arthritis. Chloroquine also has anti-SARS-CoV-2 (COVID-19) activity and anti-HIV-1 activity. |
| In vitro | METHODS: Human cholangiocarcinoma cells QBC939 were treated with Chloroquine (1.2-200 μM) for 24 h. Cell growth inhibition was detected by MTT. RESULTS: Chloroquine dose-dependently inhibited the cell growth of HRECs with an IC50 of 53.01 μM. [1] METHODS: Human non-small cell lung cancer cells A549 were treated with Chloroquine (10-80 μM) for 24 h. The expression levels of target proteins were detected by Western Blot. RESULTS: Chloroquine induced an increase in LC3-II expression and a decrease in LC3-I expression, resulting in an increase in the LC3-II/LC3-I ratio. The highest LC3-II/LC3-I ratio was observed with 40 μM Chloroquine treatment. [2] METHODS: Human osteosarcoma cells U2OS and human cervical cancer cells HeLa were treated with Chloroquine (100 μM) for 5 h. LAMP1, a marker protein for late endosomal compartment and lysosome, was detected by Immunofluorescence. RESULTS: Chloroquine increased the area of LAMP1 positive structures. [3] |
| In vivo | METHODS: To investigate the effects of Chloroquine on acute liver injury and its potential molecular mechanisms, a single dose of Chloroquine (5-50 mg/kg) was administered intraperitoneally to C57BL/6 mice 2-24 h before CCl4 (10 mL/kg) injection. RESULTS: Chloroquine pretreatment significantly inhibited CCl4-induced acute liver injury, as evidenced by a decrease in serum aminotransferases, aspartate aminotransferase, and a decrease in the histological score of liver injury, and down-regulated CCl4-induced high-mobility histone 1 (HMGB1) expression in liver tissues as well as the levels of serum HMGB1, IL-6, and TNF-α. levels. [4] METHODS: To investigate the relationship between Chloroquine and retinopathy, Chloroquine (50 mg/kg ) was administered intraperitoneally to C57/BL6 mice three times a week for six weeks. RESULTS: Chronic administration of Chloroquine induced retinopathy in mice. mRNAs for IL-1β mRNA, a component of inflammatory vesicles, and caspase1 were increased in the retinas of Chloroquine-treated mice, consistent with the initiation of inflammatory vesicles, and NTPDase1 was increased, suggesting an increase in extracellular ATP in the retina. [5] |
| Storage | Keep away from direct sunlight, Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5.25 mg/mL (16.41 mM), Suspension. DMSO : 45 mg/mL (140.68 mM), Sonication is recommended. Ethanol : 100 mg/mL (312.63 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | Toll-like Receptor (TLR) | TLR | SARS-COV-2 | SARS-CoV | SARSCoV | SARS coronavirus | rheumatoid | Parasite | malaria | Inhibitor | inhibit | inflammatory | infection | immune-modulating | Human immunodeficiency virus | HIVProtease | HIV-1 | HIV Protease | HIV | COVID-19 | Chloroquine | Autophagy | arthritis | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Aceglutamide | Hemin | Emtricitabine | Guanidine hydrochloride | Sulfamethoxazole sodium | Terbinafine hydrochloride | Hydroxychloroquine | Lamivudine | 2-Amino-2-methyl-1-propanol | Fenpyroximate | Paeonol |
| Related Compound Libraries | Bioactive Compound Library | Selected Plant-Sourced Compound Library | Anti-Cancer Clinical Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Natural Product Library | Natural Product Library for HTS | FDA-Approved Drug Library | Bitter Compound library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $66.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-07-15 | |
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-19 | ||
| $66.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-07-15 | |
|
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-04-28 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY